A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts

Bioconjugate Chemistry

Volumn 16, Issue 2, 2005, Pages 354-360

  Hamann, Philip R ^a   Hinman, Lois M ^a   Beyer, Carl F ^a   Lindh, Delores ^a   Upeslacis, Janis ^a   Shochat, Dan ^a   Mountain, Andrew ^b  

^a WYETH RESEARCH   (United States)

^b UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; CELL CULTURE; TUMORS;

ANTITUMOR EFFECT; ANTITUMOUR AGENTS; BREAST TUMOUR; CALICHEAMICIN; IMMUNOAFFINITY; IN-VITRO; OVARIAN TUMOR; SOLID TUMORS; TARGET CELLS; TUMOUR XENOGRAFTS;

MONOCLONAL ANTIBODIES;

ANTINEOPLASTIC AGENT; CALICHEAMICIN; MUCIN 1; MUCIN 1 ANTIBODY CALICHEAMICIN CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

MURINAE;

EID: 15244352751     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc049794n     Document Type: Article

References (28)

1. I. J. Am. Chem. Soc. 109, 3464-3466.
2. I with glutathione in the presence of double-stranded DNA. J. Am. Chem. Soc. 116, 1255-1271.
3. 1. Enediyne Antibiotics as Antitumor Agents (Borders, D. B., and Doyle, T. W., Eds.) pp 137-160, Marcel Dekker, New York.
4. Lee, M. D., Ellestad, G. A., and Borders, D. B. (1991) Calicheamicins: Discovery, structure, chemistry, and interaction with DNA. Acc. Chem. Res. 24, 235-243.
5. Aboud-Pirak, E., Sergent, T., Otte-Slachmuylder, C., Abarca, J., Trouet, A., and Schneider, Y.-J. (1988) Binding and endocytosis of a monoclonal antibody to a high molecular weight human milk fat globule membrane-associated antigen by cultured MCF-7 breast cancer cells. Cancer Res. 48, 3188-3196.
6. DiJoseph, J. F., Armellino, D. C., Boghaert, E. R., Khandke, K., Dougher, M., Sridharan, L., Kunz, K., Hamann, P. R., Gorovits, B., Udata, C., Moran, J. K., Popplewell, A. G., Stephens, S., Frost, P., and Damle, N. K. (2004) Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B lymphoid malignancies. Blood 103, 1807-1814.
7. Y-positive human carcinoma cells and xenografts. Clin. Cancer Res. 10, 4538-4549.
8. Baker, T. S., Bose, C. C., Caskey-Finney, H. M., King, D. J., Lawson, A. D., Lyons, A., Mountain, A., Owens, R. J., Rolfe, M. R., Sehdev, M., Yarranton, G. T., and Adair, J. R. (1994) Humanization of an anti-mucin antibody for breast and ovarian cancer therapy. Adv. Exp. Med. Biol. 1994, 35361-35382.
9. 111In-labeled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: Influence of prior administration of unlabeled hCTM01. Cancer Immunol. Immunother. 47, 39-46.
10. Hinman, L. M., Hamann, P. R., Wallace, R., Menendez, A. T., Durr, F. E., and Upeslacis, J. (1993) Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics. Cancer Res. 53, 3336-3342.
11. Hinman, L. M., Hamann, P. R., and Upeslacis, J. (1995) Preparation of conjugates to monoclonal antibodies. Enediyne Antibiotics as Antitumor Agents (Borders, D. B., and Doyle, T. W., Eds.) pp 87-105, Marcel Dekker, New York.
12. Hamann, P. R., Hinman, L. M, Beyer, C. F., Lindh, D., Upeslacis, J., Flowers, D. A., and Bernstein, I. (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjugate Chem. 13, 40-46.
13. Hamann, P. R., Hinman, L. M., Beyer, C. F., Greenberger, L., Lin, C., Lindh, D., Menendez, A. T., Wallace, R., Durr, F. E., and Upeslacis, J. (2004) An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors, choice of linker and overcoming drug resistance. Bioconjugate Chem. 16, 346-353.
14. Gillespie, A. M., Broadhead, T. J., Chan, S. Y., Owen, J., Farnsworth, A., Sopwith, M., and Coleman, R. E. (1998) Phase I study of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with epithelial ovarian cancer. Br. J. Cancer 78, 20.
15. Chan, S. Y., Gordon, A. Y., Coleman, R. Y., Hall, J. Y., Berger, M. S., Sherman, M. Y., Eten, C. Y., and Finkler, N. Y. (2003) A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol. Immunother. 52, 243-248.
16. Broadhead, T. J., Gillespie, A. M., Coleman, R. E., Owen, J., Skelton, L., Stephens, S., Farnsworth, A., Sopwith, M., and Chan, S. Y. (1998) Phase I study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with epithelial ovarian cancer: Immune response and pharmacokinetics following repeated intravenous administration. Proceedings of the American Society of Clinical Oncology, May 16-19, 1998, Los Angeles, CA, American Society of Clinical Oncology: Alexandria, VA, 1998, abstract 1693.
17. Bross, P. F., Beitz, J., Chen, G., Chen, X. H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A. R., Williams, G., and Pazdur, R. (2001) Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia, Clin. Cancer Res. 7, 1490-1496.
18. Davies, Q., Perkins, A. C., Fries, M., Watson, S., Lalani, E.-N., and Symonds, E. M. (1997) The effect of circulating antigen on the biodistribution of the engineered human antibody hCTM01 in a nude mice model. Eur. J. Nuclear Med. 24, 206-209.
19. Broadhead, T. J., Davies, Q., Van Hof, A. C., Molthoff, C. F. M., Perkins, A. C., Roos, J. C., Prinssen, W. M., Verheijen, R. H. M., den Hollander, W., Sopwith, M., Frier, M., Kenemans, P., and Symonds, E. M. (1998) Clinical study to investigate the potential of an engineered human monoclonal antibody, hCTM01, for targeted chemotherapy of ovarian cancer. Tumor Target. 3, 55-57.
20. Walter, R. B., Raden, B. W., Cronk, M. R., Bernstein, I. D., Appelbaum, F. R., and Banker, D. E. (2004) The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood 103, 4276-4284.
21. Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou. H.-R., Upeslacis, J., Shochat, D., Mountain, A., Flowers, D. A., and Bernstein, I. (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chem. 13, 47-58.
22. Melchers, F. (1970) Biosynthesis of the carbohydrate portion of immunoglobulins. Biochem. J. 119, 765-772.
23. Ozols, R. F. and Young, R. C. (1984) Chemotherapy of ovarian cancer. Semin. Oncol. 11, 251-263.
24. Newman, E. M., Lu, Y., Kashani-Sabet, M., Kesavan, V., and Scanlon, K. J. (1988) Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin. Biochem. Pharmacol. 37, 443-7.
25. Matzku, S., Bröcker, E.-B., Brüggen, J., Dippold, W. G., and Tilgen, W. (1986) Modes of binding and internalization of monoclonal antibodies to human melanoma cell lines. Cancer Res. 46, 3848-3854.
26. Goren, D., Horowitz, A. T., Tzemach, D., Tarshish, M., Zalipsky, S., and Gabizon, A. (2000) Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 6, 1949-1957.
27. Mamsoor, M. A., Svardal, A. M., and Ueland, P. M. (1992) Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal. Biochem. 200, 218-229.
28. Mistry, P. and Harrap, K. R. (1991) Historical aspects of glutathione and cancer chemotherapy. Pharm. Ther. 49, 125-132.